The Investment: $500,000
The Company: Remagine Labs is advancing wearable, electronically controlled drug delivery systems designed to transform the treatment of chronic conditions.
The University Partner: Monash University
Breakthrough Victoria: $250,000
Monash University: $250,000
About
Remagine Labs are working in collaboration with the Melbourne Centre for Nanofabrication at the Monash Technology Precinct, the University of Melbourne, and the Monash Institute of Pharmaceutical Sciences, pioneering precision, programmable drug delivery systems that enhance therapeutic outcomes and patient quality of life. The founding team is made up of: Pat Kelly – Co-founder and CEO; Professor Stan Skafidas – Co-founder, Chief Technology Officer, and Lead Researcher at the University of Melbourne; Professor Nicolas Voelcker – Advisor, and Lead Researcher at Monash University.
The Problem
Millions of people live with chronic health conditions like epilepsy and Parkinson’s disease.. These conditions often require regular medication — sometimes multiple times a day — and missing a dose or taking the wrong amount can lead to serious health issues.
Examples of common challenges:
- A person with epilepsy missing a single pill may experience a breakthrough seizure, which can be life-threatening.
- A patient with Parkinson’s disease may become “locked out” without timely medication, requiring caregiver intervention.
These treatments are often inconvenient, difficult to manage, and can lose effectiveness if not timed precisely. They also place a heavy burden on patients to remember and administer medications correctly — a challenge that too often leads to missed doses, fluctuating drug levels, and preventable complications.
The Solution
Remagine Labs is developing a wearable device that delivers medicine electronically and precisely, adapting in real time to the patient’s needs. Instead of relying on manual doses, the device can adjust automatically, improving how well the treatment works and making life easier for the patient.
This kind of technology could mean:
- No more missed doses.
- Better symptom control.
- Less stress for patients and caregivers.
- More consistent health outcomes.
Ingmar Wahlqvist, Senior Director, New Ventures and Investments Monash University,
Professor Sharon Pickering, Vice-Chancellor and Senior Vice-President Monash University
The Hon. John Brumby, Chair Breakthrough Victoria
Pat Kelly, Co-Founder and CEO, Remagine Labs